RESUNET (GETNE-2016-01): A phase II study to evaluate the efficacy and safety of the rechallenge with sunitinib in G1/G2 pancreatic neuroendocrine tumours (pNET). A Spanish Task Force Group in neuroendocrine and endocrine tumours (GETNE) study

dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorGrande, E.
dc.contributor.authorEspinosa-Olarte, P.
dc.contributor.authorSerrano, R.
dc.contributor.authorJimenez, P.
dc.contributor.authorAlonso, T.
dc.contributor.authorBenavent, M.
dc.contributor.authorCapdevila Castillon, J.
dc.contributor.authorLacasta, A.
dc.contributor.authorYaya Tur, R.
dc.contributor.authorCarmona, A.
dc.contributor.authorGallegos, I.
dc.contributor.authorRodriguez, R. M.
dc.contributor.authorCastillo Trujillo, A. O.
dc.contributor.authorMolina Cerrillo, J.
dc.contributor.authorHernando, J.
dc.contributor.authorBujedo Martinez, A.
dc.contributor.authorGarcia-Carbonero, R.
dc.contributor.authoraffiliation[Grande, E.] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Gallegos, I.] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Espinosa-Olarte, P.] Univ Hosp 12 Octubre, Dept Oncol, Pinto, Spain
dc.contributor.authoraffiliation[Serrano, R.] Hosp Reina Sofia, IMIBIC CIBERONC, Med Oncol, Cordoba, Spain
dc.contributor.authoraffiliation[Jimenez, P.] Hosp Univ Cent Asturias, Med Oncol, Oviedo, Spain
dc.contributor.authoraffiliation[Alonso, T.] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Molina Cerrillo, J.] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Benavent, M.] Hosp Virgen del Rocio, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Capdevila Castillon, J.] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Hernando, J.] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Lacasta, A.] Hosp Donostia, Med Oncol, San Sebastian, Spain
dc.contributor.authoraffiliation[Bujedo Martinez, A.] Hosp Donostia, Med Oncol, San Sebastian, Spain
dc.contributor.authoraffiliation[Yaya Tur, R.] IVO Fdn Inst Valenciano Oncol, Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Carmona, A.] Hosp Univ Morales Meseguer, Med Oncol, Murcia, Spain
dc.contributor.authoraffiliation[Rodriguez, R. M.] Univ Hosp Reina Sofia, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Castillo Trujillo, A. O.] Hosp Univ Cent Asturias HUCA, Dept Med Oncol, Oviedo, Spain
dc.contributor.authoraffiliation[Garcia-Carbonero, R.] Univ Hosp 12 Octubre, 3Med Oncol Dept, Madrid, Spain
dc.contributor.funderPfizer
dc.date.accessioned2025-01-07T13:37:54Z
dc.date.available2025-01-07T13:37:54Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.1387
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420413833/pdf
dc.identifier.urihttps://hdl.handle.net/10668/25711
dc.identifier.wosID573469101461
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS777-S778
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleRESUNET (GETNE-2016-01): A phase II study to evaluate the efficacy and safety of the rechallenge with sunitinib in G1/G2 pancreatic neuroendocrine tumours (pNET). A Spanish Task Force Group in neuroendocrine and endocrine tumours (GETNE) study
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files